指南与共识新发突发、热带与寄生虫病

美国感染病学会COVID-19患者治疗与管理指南(2022年9月)

Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (September 2022).
指南 / 共识 · Clin Infect Dis · 2024-01-01

美国感染病学会(IDSA)于2020年3月组建多学科指南小组,采用活指南方法与GRADE方法,定期系统检索同行评议及灰色文献,截至2022年5月31日检索,针对暴露前后预防、门诊轻中度、住院轻中度、住院重度非危重及危重患者共给出32条推荐。

要点

  • IDSA指南小组采用活指南方法和GRADE方法制定COVID-19治疗与管理推荐。
  • 截至2022年5月31日检索,共给出32条推荐,覆盖预防、门诊及住院不同疾病严重程度人群。
  • 指南为活指南,最新推荐可在IDSA网站查询。

核心结论

  • IDSA指南小组基于截至2022年5月31日的证据,对COVID-19治疗与管理给出32条推荐,指南为活指南,最新推荐在线可查。
  • 小组在工作启动时表示总体目标是让患者被纳入正在进行的试验。

研究设计与样本

  • 2020年3月,美国感染病学会(IDSA)组建由感染病临床医生、药师和方法学家组成的多学科指南小组。
  • 采用活指南方法并遵循快速推荐制定清单,定期对同行评议文献和灰色文献进行系统综述,采用GRADE方法评估证据确定性并形成推荐。
  • 基于截至2022年5月31日的最新检索,针对暴露前后预防、门诊轻中度、住院轻中度、住院重度非危重及危重患者给出32条推荐。

主要发现

  • 基于截至2022年5月31日的检索,IDSA指南小组针对暴露前后预防、门诊轻中度、住院轻中度、住院重度非危重及危重患者共给出32条推荐。
  • 小组在工作启动时表示总体目标是让患者被纳入正在进行的试验。
  • 此后开展了许多试验,为COVID-19治疗提供了急需的证据;随着疫情演变,仍有许多未解答的问题,希望未来试验能够回答。

关键数值与推荐

  • 基于截至2022年5月31日的最新检索,IDSA指南小组针对暴露前后预防、门诊轻中度、住院轻中度、住院重度非危重及危重患者共给出32条推荐。

临床怎么用

  • 指南旨在支持患者、临床医生和其他医疗专业人员就COVID-19患者的治疗与管理做出决策。
  • 指南为活指南,最新推荐可在https://idsociety.org/COVID19guidelines在线查询。

局限性

  • 随着疫情演变,仍有许多未解答的问题,希望未来试验能够回答。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

There are many pharmacologic therapies that are being used or considered for treatment of coronavirus disease 2019 (COVID-19), with rapidly changing efficacy and safety evidence from trials. The objective was to develop evidence-based, rapid, living guidelines intended to support patients, clinicians, and other healthcare professionals in their decisions about treatment and management of patients with COVID-19. In March 2020, the Infectious Diseases Society of America (IDSA) formed a multidisciplinary guideline panel of infectious disease clinicians, pharmacists, and methodologists with varied areas of expertise to regularly review the evidence and make recommendations about the treatment and management of persons with COVID-19. The process used a living guideline approach and followed a rapid recommendation development checklist. The panel prioritized questions and outcomes. A systematic review of the peer-reviewed and grey literature was conducted at regular intervals. The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach was used to assess the certainty of evidence and make recommendations. Based on the most recent search conducted on 31 May 2022, the IDSA guideline panel has made 32 recommendations for the treatment and management of the following groups/populations: pre- and postexposure prophylaxis, ambulatory with mild-to-moderate disease, and hospitalized with mild-to-moderate, severe but not critical, and critical disease. As these are living guidelines, the most recent recommendations can be found online at: https://idsociety.org/COVID19guidelines. At the inception of its work, the panel has expressed the overarching goal that patients be recruited into ongoing trials. Since then, many trials were conducted that provided much-needed evidence for COVID-19 therapies. There still remain many unanswered questions as the pandemic evolved, which we hope future trials can answer.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Bhimraj A, Morgan RL, Shumaker AH, et al. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (September 2022). Clin Infect Dis. 2024. PMID: 36063397. doi:10.1093/cid/ciac724

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。